Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Neoplasms benign, malignant and unspecified (incl cysts and polyps) – page 150

  • 3 924 clinical trials
  • 1 545 recruiting
  • 706 conditions
  • 31 countries

Conditions in this area

706 conditions with trials, the busiest first

Non-small cell lung cancer332Breast cancer170Plasma cell myeloma164Neoplasm158Acute myeloid leukaemia132Neoplasm malignant129Colorectal cancer metastatic106Prostate cancer102Colorectal cancer90Ovarian cancer90Hepatocellular carcinoma89Breast cancer metastatic84Non-small cell lung cancer metastatic82Chronic lymphocytic leukaemia80Malignant melanoma79Triple negative breast cancer69Squamous cell carcinoma of head and neck68Hormone receptor positive HER2 negative breast cancer62Non-small cell lung cancer stage IV59Pancreatic carcinoma57Hormone-refractory prostate cancer56Bladder cancer55Gastric cancer55Endometrial cancer53+682

Clinical trials in Neoplasms benign, malignant and unspecified (incl cysts and polyps)

3 924 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

3 924 clinical trials

Non-small cell lung cancer

Not yet recruiting

Study of amivantamab and pemetrexed for patients with non-small cell lung cancer who have EGFR exon20 insertion mutations and cannot receive platinum therapy

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Amivantamab
  • Sponsor:Fondazione Ricerca Traslazionale

Neoplasm malignant+1

Not yet recruiting

Study of WEF-001 safety and effectiveness in patients with advanced KRAS-mutant solid tumors

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:WEF-001
  • Sponsor:Auricula Biosciences Inc.

Malignant melanoma

Not yet recruiting

Long-term follow-up study of fianlimab and cemiplimab combination treatment in adult patients with melanoma

Registered drugNo placebo
Countries:IrelandIreland
  • Participants:18–64 years · 65+ years
  • Sponsor:Regeneron Pharmaceuticals Inc.

Fallopian tube cancer+1

Not yet recruiting

Study of TORL-1-23 and pegfilgrastim in women with advanced platinum-resistant ovarian, peritoneal, or fallopian tube cancer expressing CLDN6

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Sponsor:Torl Biotherapeutics LLC

Medulloblastoma

Not yet recruiting

Comparing two treatment regimens with drug combination for newly diagnosed low-risk medulloblastoma to evaluate cognitive function outcomes

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Sponsor:GPOH gGmbH

Bladder cancer

Not yet recruiting

Study of Sacituzumab Govitecan and Zimberelimab for Muscle-Invasive Bladder Cancer in Patients Unable to Take Cisplatin or Unwilling to Have Surgery

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Zimberelimab
  • Sponsor:Fondazione IRCCS Istituto Nazionale Dei Tumori

Breast neoplasm

Not yet recruiting

Study of oral TherO2-01S22 with anti-HER2 therapy in patients with metastatic breast cancer

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Vinorelbine Tartrate
  • Sponsor:Centre Regional Lutte Contre Le Cancer

Colorectal cancer metastatic

Not yet recruiting

Study on the Effects of Different Dosing Schedules of Irinotecan Hydrochloride, Calcium Folinate, and Fluorouracil in Patients with Metastatic Colorectal Cancer

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Sponsor:University Of Pecs

Hormone receptor positive HER2 negative breast cancer

Not yet recruiting

Study to Examine Distribution of Aromatase Inhibitor and Ribociclib in ER+ HER2- Early Breast Cancer in Postmenopausal Women Scheduled for Surgery

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Sponsor:Amsterdam UMC Stichting

Non-small cell lung cancer

Not yet recruiting

Evaluation of Datopotamab Deruxtecan in Patients with Non-Squamous Non-Small Cell Lung Cancer and Active Brain Metastases

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Sponsor:Medica Scientia Innovation Research S.L.

Prostate cancer

Not yet recruiting

Evaluating Technetium-99m and Cyanine-5 PSMA Tracer-Guided Surgery for Patients with Prostate Cancer

InvestigationalNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Sponsor:Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting

Neoplasm

Not yet recruiting

Study of Valemetostat Tosylate with Drug Combination for Patients with Previously Treated Solid Tumors

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Sponsor:Daiichi Sankyo Inc.

Substances studied in this area

The therapies tested most often in Neoplasms benign, malignant and unspecified (incl cysts and polyps) trials.

Infliximab65 clinical trialsVincristine Sulfate55 clinical trialsAbemaciclib45 clinical trialsIbrutinib43 clinical trialsTrifluridine31 clinical trialsAvelumab30 clinical trialsApalutamide27 clinical trialsAmivantamab25 clinical trialsZanubrutinib24 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.